Tokyo, July 9 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058402) titled 'Use-result survey to evaluate the safety and outcome of QUVIVIQ use in patients with insomnia' on July 8.
Study Type:
Observational
Primary Sponsor:
Institute - Nxera Pharma Japan Co.,Ltd
Condition:
Condition - insomnia
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the safety and efficacy of QUVIVIQ Tablets 25 mg and QUVIVIQ Tablets 50 mg in patients with insomnia under actual conditions of use.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with insomnia treated with this drug
Key exclusion criteria - None
Target Size - 500
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2025 Year 02 Month 14 Day
Date of IRB - 2025 Year 02 Month 14 Day
Anticipated trial start date - 2025 Year 07 Month 01 Day
Last follow-up date - 2030 Year 07 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066649
Disclaimer: Curated by HT Syndication.
